GRAPHITE BIO
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations.
GRAPHITE BIO
Social Links:
Industry:
Biotechnology
Founded:
2020-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.graphitebio.com
Total Employee:
101+
Status:
Active
Total Funding:
195.75 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Chroma Medicine
Chroma Medicine is a new genomic medicine company working on epigenetic editing.
Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
Generate Biomedicines
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Perceptive Advisors
Perceptive Advisors investment in Series B - Graphite Bio
Federated Kaufmann Fund
Federated Kaufmann Fund investment in Series B - Graphite Bio
RA Capital Management
RA Capital Management investment in Series B - Graphite Bio
Samsara BioCapital
Samsara BioCapital investment in Series B - Graphite Bio
Versant Ventures
Versant Ventures investment in Series B - Graphite Bio
Surveyor Capital
Surveyor Capital investment in Series B - Graphite Bio
OrbiMed
OrbiMed investment in Series B - Graphite Bio
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Graphite Bio
Rock Springs Capital
Rock Springs Capital investment in Series B - Graphite Bio
Deerfield
Deerfield investment in Series B - Graphite Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-02 | Graphite Bio Appoints Alethia Young as Chief Financial Officer |
Official Site Inspections
http://www.graphitebio.com Semrush global rank: 2.95 M Semrush visits lastest month: 5.52 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Graphite Bio"
Graphite Bio - Crunchbase Company Profile & Funding
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases.See details»
LENZ Therapeutics and Graphite Bio Announce Merger …
Nov 15, 2023 Management and Organization. ... The live webcast can be accessed here and on the Graphite Bio website at www.graphitebio.com in the Investors section or by calling 877-407-0898 or +1-201-689-8478 ...See details»
Graphite Bio - LinkedIn
Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases.See details»
Graphite Bio Company Profile 2024: Valuation, Investors
Information on acquisition, funding, cap tables, investors, and executives for Graphite Bio. Use the PitchBook Platform to explore the full profile.See details»
LENZ Therapeutics
LENZ Therapeutics is is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision, focused on an eye drop to treat presbyopia and …See details»
Graphite Bio Information - RocketReach
Graphitebio.com; yahoo.com; 3 408921XXXX; 408306XXXX; 408844XXXX; Tonia Buchholz Executive Director, Clinical Science at Graphite Bio San Francisco, California, United States …See details»
Graphite Bio Declares Special Dividend In Connection with …
Mar 8, 2024 The special dividend, which the Company estimates will be $1.03 per share of Graphite’s common stock, will be payable in cash to the stockholders of record as of March …See details»
Graphite Bio Announces Formation of Scientific Advisory Board
Mar 23, 2022 Media: Sheryl Seapy Real Chemistry 949-903-4750 [email protected] Contacts Company: Stephanie Yao VP, Communications and Investor Relations 443-739 …See details»
Company: Graphite Bio - CRISPR Medicine
Graphite Bio is a company mainly focusing on genomic engineering of haematopoietic stem cells (HSC) using CRISPR-Cas9 technology. The company has recently initiated clinical trials for its …See details»
Graphite Bio Secures $150 Million Series B Financing to Advance ...
Mar 15, 2021 Total of $195 million raised to date to support expansion and clinical advancement of Graphite Bio pipeline of targeted gene integration therapies with curative potentialSee details»
Graphite Bio - Craft
Mar 22, 2024 Graphite Bio is a gene-editing company focused on the development of therapies for patients suffering from life-threatening genetic diseases. It offers products candidates to …See details»
Graphite Bio Plans to Move New Way of Gene Editing Into Sickle...
Sep 22, 2020 The approach taken by Graphite Bio pairs two approaches that have emerged in gene therapies — CRISPR/Cas9 gene editing and adeno-associated viruses (AAV). …See details»
Graphite pulls off $238M IPO to sketch out path to clinic for gene ...
Jun 25, 2021 RELATED: Novartis, Gates Foundation ally on in vivo sickle cell gene therapy Graphite’s gene-editing treatments are based on technology developed at Stanford University …See details»
Graphite Bio Expands Leadership Team with Accomplished …
Nov 9, 2020 Earlier at Celgene, Ms. Stultz served as corporate vice president, global project leadership, hematology and oncology, directing the clinical project organization worldwide and …See details»
Graphite founder sets up new biotech to save sickle cell program
Dec 8, 2023 Matthew Porteus, M.D., Ph.D., is trying to write another chapter for his sickle cell disease project. Three years after Graphite Bio launched to build on his work, Porteus has …See details»
Graphite Bio debuts with $45M to cure sickle cell disease using …
Sep 16, 2020 The biggest challenge for scientists working on genome engineering, according to Josh Lehrer, M.D., CEO of the newly announced Graphite Bio, is targeting DNA at a specific …See details»
Graphite Bio Secures $150 Million Series B Financing to ... - BioSpace
Mar 15, 2021 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration …See details»
CRISPR start-up Graphite Bio launches with $45 million for …
Sep 16, 2020 Graphite calls the fixing technique targeted DNA integration. Fixing the mutation in the β-globin gene requires three components: the Cas9 enzyme to cut the DNA, the guide …See details»
Graphite Bio Announces Pricing of Upsized Initial Public Offering
Jun 25, 2021 Investor Relations: Stephanie Ascher Stern IR, Inc. 212-362-1200 [email protected] Media Contact: Christy Curran Sam Brown, Inc. 615-414-8668 …See details»
Graphite Bio: gene editing blood stem cells for sickle cell disease
Jul 7, 2021 Ex vivo gene editing of hematopoietic stem cells using CRISPR–Cas9 and adeno-associated virus serotype 6 is ready for trials in people with sickle-cell disease.See details»